$2.37
0.00% day before yesterday
Nasdaq, Aug 30, 12:22 am CET
ISIN
US45773H2013
Symbol
INO

Inovio Pharmaceuticals, Inc. Stock price

$2.37
+0.94 65.73% 1M
+0.39 19.70% 6M
+0.54 29.51% YTD
-4.95 67.62% 1Y
-25.47 91.49% 3Y
-141.51 98.35% 5Y
-87.51 97.36% 10Y
-122.43 98.10% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.09 3.66%
ISIN
US45773H2013
Symbol
INO
Industry

Key metrics

Basic
Market capitalization
$126.0m
Enterprise Value
$78.4m
Net debt
positive
Cash
$47.6m
Shares outstanding
36.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
699.7 | 1,433.4
EV/Sales
435.6 | 892.2
EV/FCF
negative
P/B
4.4
Financial Health
Equity Ratio
60.5%
Return on Equity
-156.6%
ROCE
-262.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$180.0k | $87.9k
EBITDA
$-92.8m | -
EBIT
$-95.9m | $-97.1m
Net Income
$-87.8m | $-69.9m
Free Cash Flow
$-94.9m
Growth (TTM | estimate)
Revenue
-69.5% | -60.1%
EBITDA
25.6% | -
EBIT
24.9% | 13.6%
Net Income
27.9% | 34.8%
Free Cash Flow
15.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-50,919.0% | -
EBIT
-52,579.3%
Net
-48,141.1% | -79,567.2%
Free Cash Flow
-52,047.7%
More
EPS
$-2.3
FCF per Share
$-2.6
Short interest
10.7%
Employees
134
Rev per Employee
$0.0
Show more

Is Inovio Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Inovio Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast:

7x Buy
70%
3x Hold
30%

Analyst Opinions

10 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast:

Buy
70%
Hold
30%

Financial data from Inovio Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.18 0.18
69% 69%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 34 34
17% 17%
18,778%
- Research and Development Expense 62 62
19% 19%
34,572%
-93 -93
26% 26%
-51,572%
- Depreciation and Amortization 3.03 3.03
8% 8%
1,683%
EBIT (Operating Income) EBIT -96 -96
25% 25%
-53,251%
Net Profit -88 -88
28% 28%
-48,756%

In millions USD.

Don't miss a Thing! We will send you all news about Inovio Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inovio Pharmaceuticals, Inc. Stock News

Neutral
PRNewsWire
6 days ago
Complete submission of the Biologics License Application (BLA) remains on track for 2H25 with the goal of file acceptance by U.S. Food and Drug Administration (FDA) by end of 2025 PLYMOUTH MEETING, Pa. , Aug. 26, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, c...
Neutral
PRNewsWire
7 days ago
PLYMOUTH MEETING, Pa. , Aug. 25, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that a pre-recorded presentation from the Company will be available on demand as a part of the H.C.
Neutral
Seeking Alpha
20 days ago
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Jacqueline E. Shea - CEO, President & Director Jennie Willson - Corporate Participant Investor Relations - Corporate Participant Michael Sumner - Chief Medical Officer Peter D.
More Inovio Pharmaceuticals, Inc. News

Company Profile

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The firm's drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Head office United States
CEO Jacqueline Shea
Employees 134
Founded 1983
Website www.inovio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today